Business Context and Reporting Period
This Form 8-K Current Report was filed by Madrigal Pharmaceuticals, Inc. on May 17, 2021. The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the departure of the previous CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: $450,000 annually.
- Signing Bonus: $75,000 (subject to 50% recapture upon certain early departures).
- Target Annual Cash Bonus: 40% of base salary.
- Stock Option Grant: 65,000 shares with a four-year vesting schedule (25% on first anniversary, remainder ratably).
Material Changes
The primary material change is the leadership transition in the finance department effective May 17, 2021:
- Appointment: Alex Howarth was appointed Chief Financial Officer.
- Departure: Marc Schneebaum stepped down as Senior Vice President and Chief Financial Officer but remains an employee through June 30, 2021, to assist with the transition.
- Reason for Departure: The filing explicitly states there was no disagreement between Mr. Schneebaum and the Company regarding accounting principles or business policies.
Outlook, Risks, and Contingencies
Management Commentary: The Board highlighted Mr. Howarth's 25+ years of experience in biopharmaceutical companies, including roles at Akcea Therapeutics, Lycera Corporation, and GlaxoSmithKline.
Severance and Change of Control: Mr. Howarth is an "at-will" employee covered by a severance agreement. In the event of a "Qualifying Separation" (termination without Cause or resignation for Good Reason), benefits generally include:
- 12 months of base salary.
- Accrued earned bonus and specified target bonus opportunities (if following a change of control).
- Equity vesting rights.
- 12 months of medical benefits continuation.
Risks: The signing bonus is subject to recapture if Mr. Howarth departs early under certain conditions. Severance obligations are contingent upon the execution of a release of claims.
Investor Verification Checklist
- Verify the exact closing price of MDGL stock on May 17, 2021, to determine the exercise price of the 65,000 stock options granted to Mr. Howarth.
- Review the full text of the employment and severance agreement (Exhibit 10, if filed separately or referenced) to understand specific definitions of "Cause" and "Good Reason."
- Confirm the transition timeline for Marc Schneebaum's departure through June 30, 2021.
- Check subsequent filings for any updates on the Company's financial performance or additional executive appointments.